Coloplast confident that wound care products meet new reimbursement requirements in the US
Coloplast believes that the products from Kerecis, which the company acquired last year, comply with new regulations in the US.
by MARKETWIRE
Coloplast is confident in its ability to meet potential new requirements for wound care products in the US, the company says, after seven private US health insurers that administer Medicare last week released a draft policy that could affect the use of wound care products for diabetic foot ulcers and venous leg ulcers.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
